You are here

  • Home
  • Archive
  • Volume 10, Issue 6
  • Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy

Citation Tools

Article menu
Immunotherapy biomarkers
Original research
Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Attrill GH, Owen CN, Ahmed T, et al
Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy
Journal for ImmunoTherapy of Cancer 2022;10:e004771. doi: 10.1136/jitc-2022-004771